News

Those in the Scleroderma community are taking note of recent news that Bayer HealthCare will be initiating a randomized, double-blind, placebo-controlled, Phase II clinical study to investigate efficacy and safety of riociguat in patients suffering from diffuse cutaneous systemic sclerosis (dcSSc), according to an announcement by the company. The study is…

Inventiva Pharma’s lead product, IVA337, recently received a positive review by The European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) to treat Systemic Sclerosis. The news is a step in the right direction for patients in Europe suffering from the disease, and is also yet another positive sign of…

The University of California San Francisco (UCSF) will be hosting a free, live webinar entitled “Emerging Therapies in Pulmonary Fibrosis: Their Relevance for Scleroderma Patients,” to be conducted by the university’s Director of Biological Research for the Interstitial Lung Disease Program, Dr. Paul Wolters. It will be broadcasted on the Scleroderma…

Predicting mortality and morbidity for scleroderma patients, either of the limited or diffusive cutaneous systemic sclerosis subtypes (lcSSc and dcSSc, respectively) is important to both clinicians and the affected individuals to help determine how patients may respond to certain types of treatments. To assign predictions to patients, researchers involved…

A diagnosis of systemic sclerosis (SSc) can be extremely stressful for patients, and it is important that patients receive appropriate support to reduce emotional distress. Some patients may benefit from an interdisciplinary care program that incorporates physical therapy, occupational therapy, and specialized nurse care, according to a case study…

Although women have a greater risk for systemic sclerosis (SSc), they may actually experience a lesser degree of symptoms. An international study based in Cochin Hospital in Paris extracted data for 9,182 patients with SSc from the European League Against Rheumatism (EULAR) scleroderma trials and research study cohort and…